By the way, it's also time to name the drug
Immuron Limited is today pleased to announce the topline results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study. The results show that Immuron’s oral IMM-124E shows improvement in liver injury and significantly reduces blood levels of LPS (lipopolysaccharide), a known mediator of liver inflammation in patients with NASH. The discovery could have far-reaching opportunities for the effective treatment of a broad range of diseases relating to LPS inflammation beyond NASH.
The clinical study results show;
- First-in class anti-LPS mechanism of action confirmed for IMM-124E.
- Excellent safety and tolerability.
- Statistically significant reduction in serum endotoxin/lipopolysaccharide (LPS) levels compared to placebo.
- Statistically significant reduction in mean serum ALT in patients with elevated pre-treatment ALT
- Statistically significant reduction of additional serum NASH biomarkers associated with liver damage –AST and CK-18.
- IMM-124E retained within the GI tract and not absorbed into the bloodstream, contributing to favourable safety profile.
- Anti-LPS mechanism of IMM-124E may have wider therapeutic applications beyond NASH.
- Forums
- ASX - By Stock
- IMC
- Reminder of What We Have in IMM-124E
Reminder of What We Have in IMM-124E
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMC (ASX) to my watchlist
|
|||||
Last
9.8¢ |
Change
0.001(1.03%) |
Mkt cap ! $22.11M |
Open | High | Low | Value | Volume |
9.8¢ | 9.8¢ | 9.8¢ | $3.639K | 37.13K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2306 | 9.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.9¢ | 28455 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 31198 | 0.096 |
1 | 2728 | 0.095 |
2 | 117032 | 0.093 |
1 | 20602 | 0.092 |
1 | 80000 | 0.091 |
Price($) | Vol. | No. |
---|---|---|
0.099 | 26999 | 2 |
0.100 | 171349 | 4 |
0.105 | 108309 | 4 |
0.110 | 139728 | 2 |
0.115 | 66632 | 2 |
Last trade - 10.10am 24/07/2024 (20 minute delay) ? |
Featured News
IMC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO & MD
Charles Armstrong
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online